Latest Stock Buy or Sell? Make More Informed Decisions!

We've underperformed for so many years. The TSX is pretty lumpy, so there will be times when we actually outperform, which is great.

Performance is explained by our concentration in gold, metals, copper, banks & financials (which have done extraordinarily recently, with great earnings). There's also natural gas, which is finally in a bull market after years of slumber. 

Lots of tailwinds with these Canadian nation-building projects, which can be pretty stimulative and have a multiplier effect. We have a lot of power companies as well; so far they've been stable places to be, but are now fueling the buildout of the data centre push. Investors are getting pretty excited.

Put it all together, and the TSX has been just stunning.

It was a very scary, rocky year. April saw the administration announcing a financial reorganization that would right the ship from benefiting Wall Street investors for the last 40 years to benefitting Main Street instead.

CUSMA covers about 93% of goods that flow over the border. Trump toned down a lot of the tariff rhetoric to a point where he could, perhaps, claim a victory. Goods are still going through and there haven't been too many higher costs for Canadians, who haven't really seen that much inflation.

Canadian economy has been solid, and we just got more evidence of that today.

Usually the acquiring company's stock does fall, so that's normal. There's going to be incredible regulatory scrutiny.  He predicts the deal won't get done, it's too anti-competitive. The White House is already taking a dim view of it. If the 1 in 4 odds come through and the deal does happen, it would be incredible for NFLX. We're talking about a 100-year library of the best movies.

Last quarter, missed on some Brazilian tax issues and so it missed on earnings. Big competition. But Q3 had the best sales ever, revenue was up 17% YOY, raised guidance. Aiming to double revenues by 2030. Also trying to leverage generative AI. Growing ~20%, trading at ~27x. Still really good value.

Being investigated for some mergers as potentially anti-competitive. Q3 was in line. Strength in US patients and SaaS segments. Affirmed outlook. Margins beat. Revenue growth up 56% YOY, organic growth up 19%. Analysts have upgraded.

Because of acquisitions, earnings outlook not steady enough. Very cheap at 9.5x PE for 2027. For riskier, more speculative capital, you can own it in a non-registered account.

Does have a moat. Does most of the AMZN shipping. Very capital-intensive, and investors need to be aware of that. Stock got far too cheap. CEO transition. Most things are up this year, and investors are looking for tax-loss selling candidates. Take that away, and he sees it being up 10-15% in January.

As trade normalizes, should see reacceleration in growth. Trades ~15x PE for 2027, modelling ~14% growth. Not a bad name to add to right now.

M&A model. They buy something, fix their balance sheet over time, and then do it again. Cyclical.

Cut dividend more than expected, by 60%. Hard to say if they did it because the fundamentals are getting worse, or just to be conservative. Stock rallied on the news, which is a good sign -- investors are relieved that balance sheet will get better. No forward guidance given. Exacerbated by tax-loss selling. 

Pretty cheap. Not a lot of downside from here, though won't go anywhere for the next month. Key is they need to see some occupancy gains beyond 90%.

An exchange in Singapore for commodities. No real earnings yet, very speculative. Met with management a couple of years ago, very impressed. Rumours of TSX inclusion, didn't happen, stock's pulled back. 

Please don't put this in your RRSP. If you don't mind having a loss in a non-registered account if it doesn't work out, a good stock to place a bet on. $47 is a good place to add. Be aware that these moon shots don't always pan out.